Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $14.6700 (-0.91%) ($14.4050 - $14.7800) on Thu. Aug. 20, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.74% (three month average) | RSI | 55 | Latest Price | $14.6700(-0.91%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | FOLD declines -0.8% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(51%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -1.87% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-12%) IYT(-6%) XLC(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.87% (StdDev 3.74%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $14.8 | 5 Day Moving Average | $14.69(-0.14%) | 10 Day Moving Average | $14.78(-0.74%) | 20 Day Moving Average | $14.8(-0.88%) | To recent high | -7.7% | To recent low | 34.2% | Market Cap | $3.788b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |